Clinical Trial Update: A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease [Phase 1]

View source ↗

Summary

Alzinova's ALZ-101 Phase 1 trial in early Alzheimer's disease completed, assessing safety, tolerability, and immunogenicity. The study provides initial human da…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ALZ-101

Snippet

Sponsor: Alzinova AB | Conditions: Alzheimer Disease, Dementia Alzheimers | Phase 1 | Status: COMPLETED